Item 8.01 Other Events.
On September 29, 2020, CTI BioPharma Corp. (the "Company") issued a press
release announcing the Company's plans to submit a new drug application seeking
FDA approval of pacritinib for the treatment of myelofibrosis patients with
severe thrombocytopenia. A copy of the press release is attached as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Description
99.1 Press release dated September 29, 2020
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses